1
|
Ambrosini S, Mohammed SA, Gorica E, Herwig M, Karsay G, Hornemann T, Ruschitzka F, Hamdani N, Costantino S, Paneni F. The histone methyltransferase SETD2 drives cardiometabolic heart failure with preserved ejection fraction. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent in patients with cardiometabolic disorders and associates with a poor outcome. Pathological gene expression in heart failure is accompanied by changes in active histone marks without major alterations in DNA methylation. Histone 3 trimethylation at lysine 36 (H3k36me3) – an active chromatin mark induced by the methyltransferase SETD2 – was recently found among the top epigenetic signatures in failing human hearts. Yet, the role of SETD2/H3k36me3 in heart failure is poorly understood.
Purpose
To investigate whether SETD2 participates in the transcriptional regulation of cardiometabolic HFpEF.
Methods
Mice with cardiomyocyte-specific deletion of SETD2 (c-SETD2−/−) and control littermates (SETD2fl/fl) were generated and subjected to high fat diet feeding and L-NAME treatment for 15 weeks to induce cardiometabolic HFpEF. Histology, mouse echocardiography (Vevo3100) and Treadmill exhaustion test were performed. ChIP-Seq datasets were employed to determine the biological pathways regulated by H3k36me3, whereas chromatin immunoprecipitation assays (ChIP) were performed to investigate SETD2/H3k36me3 enrichment on gene promoters. SETD2 gain- and loss-of-function experiments were performed in cultured cardiomyocytes (CMs) exposed to palmitic acid. Lipotoxic injury was assessed by mass spectrometry (MS)-based quantification of lipid species, autophagic flux (by Western blot) and apoptosis (by Caspase-3 activity assay). SETD2/H3k36me3 were also investigated in left ventricular myocardial specimens from patients with HFpEF and were correlated to passive stiffness.
Results
ChIP-Seq in mouse CMs showed a strong enrichment of SETD2/H3k36me3 in pathways underpinning triglyceride synthesis. SETD2 and H3k36me3 were upregulated in HFpEF vs. control mouse hearts and were highly enriched on the promoter of sterol regulatory element-binding transcription factor 1 (SREBF1) gene. These changes were associated with SREBF1 upregulation, myocardial triglyceride accumulation and lipotoxic damage. In HFpEF mice, cardiomyocyte-specific deletion of SETD2 prevented hypertrophic remodeling, diastolic dysfunction and lung congestion while improving exercise tolerance. Moreover, SETD2 deletion blunted H3K36me3 enrichment on SREBF1 promoter thus preventing SREBF1-related lipid accumulation, impaired autophagic flux and apoptosis. In cultured CMs exposed to palmitic acid, SETD2 depletion prevented H3k36me3-driven SREBF1 upregulation, whereas SETD2 overexpression recapitulated lipotoxic damage. SREBF1 knockdown prevented lipotoxic injury in SETD2-overexpressing CMs, suggesting its direct role in SETD2 signalling. Finally, SETD2 was upregulated in myocardial samples from obese patients with HFpEF and positively correlated with cardiomyocyte stiffness, a major feature of HFpEF.
Conclusions
SETD2 may represent an attractive molecular target for the prevention of cardiometabolic HFpEF.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): University of Zürich
Collapse
Affiliation(s)
- S Ambrosini
- University of Zurich , Schlieren , Switzerland
| | | | - E Gorica
- University of Zurich , Schlieren , Switzerland
| | - M Herwig
- Ruhr University Bochum , Bochum , Germany
| | - G Karsay
- University Hospital Zurich, Institute of Clinical Chemistry , Zurich , Switzerland
| | - T Hornemann
- University Hospital Zurich, Institute of Clinical Chemistry , Zurich , Switzerland
| | - F Ruschitzka
- University Hospital Zurich, University Heart Center, Cardiology , Zurich , Switzerland
| | - N Hamdani
- Ruhr University Bochum , Bochum , Germany
| | | | - F Paneni
- University of Zurich , Schlieren , Switzerland
| |
Collapse
|
2
|
Eichhoff O, Stoffel C, Briker L, Turko P, Karsai G, Paulitschke V, Zamboni N, Balazs Z, Tastanova A, Wegmann R, Mena J, Viswanathan V, TuPro C, Krauthammer M, Schreiber S, Hornemann T, Distel M, Snijder B, Dummer R, Levesque M. ROS induction as a strategy to target persister cancer cell metabolism. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00815-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Hornemann T, Wipfli F. Metabolic indicators of an altered sphingolipid metabolism are biomarkers for non-alcoholic fatty liver disease. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Lone M, Hornemann T. MOTOR NEURON DISORDERS AND NEUROPATHIES. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Weyler J, Verrijken A, Hornemann T, Vonghia L, Dirinck E, von Eckardstein A, Vanwolleghem T, Michielsen P, Peiffer F, Driessen A, Hubens G, Staels B, Francque S, Van Gaal L. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease. Acta Diabetol 2021; 58:319-327. [PMID: 33084982 DOI: 10.1007/s00592-020-01612-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Accepted: 09/25/2020] [Indexed: 12/18/2022]
Abstract
BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is the most important cause of chronic liver disease in the western world. Steatosis can be accompanied by inflammation and cell damage (non-alcoholic steatohepatitis, NASH), and even liver fibrosis. Sphingolipids are a heterogeneous class of lipids and essential components of the plasma membrane and plasma lipoproteins. The atypical class of deoxy-sphingolipids has been implicated in the metabolic syndrome and type 2 diabetes. AIM To determine if circulating (deoxy)sphingolipids are associated with NAFLD and its different entities, steatosis, inflammatory changes (inflammation and ballooning) and fibrosis. METHODS Sphingolipids were analysed by LC-MS after hydrolysing the N-acyl and O-linked headgroups in plasma of obese adults who underwent a liver biopsy in suspicion of NAFLD. RESULTS Two-hundred and eighty-eight patients were included. There was no association between typical sphingolipids and NAFLD and its different entities. There was a significant association between the presence of steatosis and the concentrations of deoxy-sphinganine [exp(B) 11.163 with CI (3.432, 36.306) and p < 0.001] and deoxy-sphingosine [exp(B) 8.486 with CI (3.437, 20.949) and p < 0.001]. There was no association between these deoxy-sphingolipids and activity of the steatohepatitis, nor was there any association with fibrosis. Differences in deoxy-sphingolipids also correlated independently with the presence of the metabolic syndrome, but not diabetes. CONCLUSION Deoxy-sphingolipids are elevated in patients with steatosis compared to those without fatty liver, but not different between the different NAFLD subtypes, suggesting that deoxy-sphingolipid bases might be involved in steatogenesis, but not in the further progression of NAFLD to NASH nor in fibrogenesis.
Collapse
Affiliation(s)
- J Weyler
- Department of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium.
- Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, Belgium.
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium.
| | - A Verrijken
- Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, Belgium
- Department of Endocrinology, Diabetology and Metabolic Diseases, Antwerp University Hospital, Edegem, Belgium
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
| | - T Hornemann
- Institute for Clinical Chemistry, University Hospital Zurich and Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
- Competence Center for Systems Physiology and Metabolic Diseases, University of Zurich, Zurich, Switzerland
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
| | - L Vonghia
- Department of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium
- Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, Belgium
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
| | - E Dirinck
- Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, Belgium
- Department of Endocrinology, Diabetology and Metabolic Diseases, Antwerp University Hospital, Edegem, Belgium
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
| | - A von Eckardstein
- Institute for Clinical Chemistry, University Hospital Zurich and Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
| | - T Vanwolleghem
- Department of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium
- Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, Belgium
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
| | - P Michielsen
- Department of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium
- Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, Belgium
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
| | - F Peiffer
- Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, Belgium
- Department of Endocrinology, Diabetology and Metabolic Diseases, Antwerp University Hospital, Edegem, Belgium
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
| | - A Driessen
- Department of Pathology, Antwerp University Hospital, Edegem, Belgium
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
| | - G Hubens
- Department of Pathology, Antwerp University Hospital, Edegem, Belgium
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
| | - B Staels
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000, Lille, France
| | - S Francque
- Department of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium.
- Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, Belgium.
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium.
| | - L Van Gaal
- Laboratory of Experimental Medicine and Paediatrics, University of Antwerp, Antwerp, Belgium
- Department of Endocrinology, Diabetology and Metabolic Diseases, Antwerp University Hospital, Edegem, Belgium
- Department of Abdominal Surgery, Antwerp University Hospital, Edegem, Belgium
| |
Collapse
|
6
|
Ouwenbroek A, Hornemann T, Weis J, Schulz J, Gess B, Dohrn M. P49 How borderline HbA1c levels may potentially build a bridge between chronic idiopathic axonal polyneuropathy (CIAP) and diabetic polyneuropathy. Clin Neurophysiol 2020. [DOI: 10.1016/j.clinph.2019.12.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
7
|
Carreira AC, Santos TC, Lone MA, Zupančič E, Lloyd-Evans E, de Almeida RFM, Hornemann T, Silva LC. Mammalian sphingoid bases: Biophysical, physiological and pathological properties. Prog Lipid Res 2019:100995. [PMID: 31445071 DOI: 10.1016/j.plipres.2019.100995] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2018] [Revised: 05/17/2019] [Accepted: 05/20/2019] [Indexed: 12/19/2022]
Abstract
Sphingoid bases encompass a group of long chain amino alcohols which form the essential structure of sphingolipids. Over the last years, these amphiphilic molecules were moving more and more into the focus of biomedical research due to their role as bioactive molecules. In fact, free sphingoid bases interact with specific receptors and target molecules and have been associated with numerous biological and physiological processes. In addition, they can modulate the biophysical properties of biological membranes. Several human diseases are related to pathological changes in the structure and metabolism of sphingoid bases. Yet, the mechanisms underlying their biological and pathophysiological actions remain elusive. Within this review, we aimed to summarize the current knowledge on the biochemical and biophysical properties of the most common sphingoid bases and to discuss their importance in health and disease.
Collapse
Affiliation(s)
- A C Carreira
- iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal; Centro de Química e Bioquímica (CQB) e Centro de Química Estrutural (CQE), Faculdade de Ciências, Universidade de Lisboa, Ed. C8, Campo Grande, 1749-016 Lisboa, Portugal; Sir Martin Evans Building, School of Biosciences, Cardiff University, Cardiff, United Kingdom
| | - T C Santos
- iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal; Centro de Química-Física Molecular - Institute of Nanoscience and Nanotechnology (CQFM-IN) and IBB-Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal; Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland
| | - M A Lone
- Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland
| | - E Zupančič
- iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| | - E Lloyd-Evans
- Sir Martin Evans Building, School of Biosciences, Cardiff University, Cardiff, United Kingdom
| | - R F M de Almeida
- Centro de Química e Bioquímica (CQB) e Centro de Química Estrutural (CQE), Faculdade de Ciências, Universidade de Lisboa, Ed. C8, Campo Grande, 1749-016 Lisboa, Portugal
| | - T Hornemann
- Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland
| | - L C Silva
- iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal; Centro de Química-Física Molecular - Institute of Nanoscience and Nanotechnology (CQFM-IN) and IBB-Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
| |
Collapse
|
8
|
Carreira AC, Santos TC, Lone MA, Zupančič E, Lloyd-Evans E, de Almeida RFM, Hornemann T, Silva LC. Mammalian sphingoid bases: Biophysical, physiological and pathological properties. Prog Lipid Res 2019; 75:100988. [PMID: 31132366 DOI: 10.1016/j.plipres.2019.100988] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2018] [Revised: 05/17/2019] [Accepted: 05/21/2019] [Indexed: 12/11/2022]
Abstract
Sphingoid bases encompass a group of long chain amino alcohols which form the essential structure of sphingolipids. Over the last years, these amphiphilic molecules were moving more and more into the focus of biomedical research due to their role as bioactive molecules. In fact, free sphingoid bases interact with specific receptors and target molecules, and have been associated with numerous biological and physiological processes. In addition, they can modulate the biophysical properties of biological membranes. Several human diseases are related to pathological changes in the structure and metabolism of sphingoid bases. Yet, the mechanisms underlying their biological and pathophysiological actions remain elusive. Within this review, we aimed to summarize the current knowledge on the biochemical and biophysical properties of the most common sphingoid bases and to discuss their importance in health and disease.
Collapse
Affiliation(s)
- A C Carreira
- iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa 1649-003, Portugal; Centro de Química e Bioquímica (CQB) e Centro de Química Estrutural (CQE), Faculdade de Ciências, Universidade de Lisboa, Ed. C8, Campo Grande, Lisboa 1749-016, Portugal; Sir Martin Evans Building, School of Biosciences, Cardiff University, Cardiff, UK
| | - T C Santos
- iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa 1649-003, Portugal; Centro de Química-Física Molecular - Institute of Nanoscience and Nanotechnology (CQFM-IN), IBB-Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal; Institute for Clinical Chemistry, University Hospital Zurich, Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland
| | - M A Lone
- Institute for Clinical Chemistry, University Hospital Zurich, Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland
| | - E Zupančič
- iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa 1649-003, Portugal
| | - E Lloyd-Evans
- Sir Martin Evans Building, School of Biosciences, Cardiff University, Cardiff, UK
| | - R F M de Almeida
- Centro de Química e Bioquímica (CQB) e Centro de Química Estrutural (CQE), Faculdade de Ciências, Universidade de Lisboa, Ed. C8, Campo Grande, Lisboa 1749-016, Portugal
| | - T Hornemann
- Institute for Clinical Chemistry, University Hospital Zurich, Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland
| | - L C Silva
- iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, Lisboa 1649-003, Portugal; Centro de Química-Física Molecular - Institute of Nanoscience and Nanotechnology (CQFM-IN), IBB-Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal.
| |
Collapse
|
9
|
Lone MA, Santos T, Alecu I, Silva LC, Hornemann T. 1-Deoxysphingolipids. Biochim Biophys Acta Mol Cell Biol Lipids 2019; 1864:512-521. [PMID: 30625374 DOI: 10.1016/j.bbalip.2018.12.013] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Revised: 12/19/2018] [Accepted: 12/20/2018] [Indexed: 12/14/2022]
Abstract
Sphingolipids (SLs) are fundamental components of eukaryotic cells. 1-Deoxysphingolipids differ structurally from canonical SLs as they lack the essential C1-OH group. Consequently, 1-deoxysphingolipids cannot be converted to complex sphingolipids and are not degraded over the canonical catabolic pathways. Pathologically elevated 1-deoxySLs are involved in several disease conditions. Within this review, we will provide an up-to-date overview on the metabolic, physiological and pathophysiological aspects of this enigmatic class of "headless" sphingolipids.
Collapse
Affiliation(s)
- M A Lone
- Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland
| | - T Santos
- Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland; iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal; Centro de Química-Física Molecular and IN-Institute of Nanoscience and Nanotechnology, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
| | - I Alecu
- Neural Regeneration Laboratory, India Taylor Lipidomic Research Platform, Department of Biochemistry, Microbiology and Immunology, Ottawa Institute of Systems Biology, Ottawa Brain and Mind Research Institute, University of Ottawa, Canada
| | - L C Silva
- iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal; Centro de Química-Física Molecular and IN-Institute of Nanoscience and Nanotechnology, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
| | - T Hornemann
- Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland.
| |
Collapse
|
10
|
Costantino S, Akhmedov A, Melina G, Mohammed SA, Wijnen W, Othman A, Hornemann T, Volpe M, Sinatra R, Camici GG, Luscher TF, Paneni F. 1431Modulation of JunD by miR-494-3p causes intra-myocardial lipid accumulation and obesity cardiomyopathy: a study in mice and humans. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.1431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- S Costantino
- University of Zurich, Center for Molecular Cardiology, Schlieren, Switzerland
| | - A Akhmedov
- University of Zurich, Center for Molecular Cardiology, Schlieren, Switzerland
| | - G Melina
- Sapienza University of Rome, Department of Cardiac Surgery, Sant'Andrea Hospital, Rome, Italy
| | - S A Mohammed
- University of Zurich, Center for Molecular Cardiology, Schlieren, Switzerland
| | - W Wijnen
- University of Zurich, Center for Molecular Cardiology, Schlieren, Switzerland
| | - A Othman
- University Hospital Zurich, Institute for Clinical Chemistry, Zurich, Switzerland
| | - T Hornemann
- University Hospital Zurich, Institute for Clinical Chemistry, Zurich, Switzerland
| | - M Volpe
- Sapienza University of Rome, Department of Clinical and Molecular Medicine, Rome, Italy
| | - R Sinatra
- Sapienza University of Rome, Department of Cardiac Surgery, Sant'Andrea Hospital, Rome, Italy
| | - G G Camici
- University of Zurich, Center for Molecular Cardiology, Schlieren, Switzerland
| | - T F Luscher
- University of Zurich, Center for Molecular Cardiology, Schlieren, Switzerland
| | - F Paneni
- University of Zurich, Center for Molecular Cardiology, Schlieren, Switzerland
| |
Collapse
|
11
|
Saied EM, Le TLS, Hornemann T, Arenz C. Synthesis and characterization of some atypical sphingoid bases. Bioorg Med Chem 2018; 26:4047-4057. [PMID: 29960730 DOI: 10.1016/j.bmc.2018.06.031] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Revised: 06/19/2018] [Accepted: 06/23/2018] [Indexed: 11/18/2022]
Abstract
Sphingolipids are ubiquitous and abundant components of all eukaryotic and some prokaryotic organisms. Sphingolipids show a large structural variety not only between the different species, but also within an individual cell. This variety is not limited to alterations in the polar headgroups of e.g. glycosphingolipids, but also affects the lipophilic anchors comprised of different fatty acids on the one hand and different sphingoid bases on the other hand. The structural variations within different sphingoid bases e.g. in pathogens can be used to identify novel biomarkers and drug targets and the specific change in the profile of common and uncommon sphingolipids are associated with pathological conditions like diabetes or cancer. Therefore, the emerging field of sphingolipidomics is dedicated to collect data on the sphingolipidome of a cell and hence to assign changes therein to certain states of a cell or to pathological conditions. This powerful tool however is still limited by the availability of structural information about the individual lipid species as well as by the availability of appropriate internal standards for quantification. Herein we describe the synthesis of a variety of 1-deoxy-sphingoid bases. 1-DeoxySphingolipids have recently acquired significant attention due to its pathological role in the rare inherited neuropathy, HSAN1 but also as predictive biomarkers in diabetes type II. Some of the compounds synthesized and characterized herein, have been used and will be used to elucidate the correct structure of these disease-related lipids and their metabolites.
Collapse
Affiliation(s)
- Essa M Saied
- Institute for Chemistry, Humboldt Universität zu Berlin, Brook-Taylor-Str. 2, 12489 Berlin, Germany; Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt
| | - Thuy Linh-Stella Le
- Institute for Chemistry, Humboldt Universität zu Berlin, Brook-Taylor-Str. 2, 12489 Berlin, Germany
| | - T Hornemann
- University of Zurich; University Hospital of Zurich, Switzerland
| | - Christoph Arenz
- Institute for Chemistry, Humboldt Universität zu Berlin, Brook-Taylor-Str. 2, 12489 Berlin, Germany.
| |
Collapse
|
12
|
Kugathasan U, Laurá M, Tomaselli P, Evans M, Pittmann A, Sinclair C, Hornemann T, Suriyanarayanan S, Phadke R, Lauria G, Lombardi R, Polke J, Bennett D, Houlden H, Blake J, Reilly M. Hereditory Sensory Neuropathy Type 1 ( SPTLC1 ): phenotypic variation in patients with the English founder mutation. Neuromuscul Disord 2017. [DOI: 10.1016/s0960-8966(17)30296-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
13
|
Schofield J, Steiner R, Liu Y, Hobkirk J, Siahmansur T, Pemberton P, Azmi S, Alecu I, Whitelaw D, Carroll S, von Eckardstein A, Hornemann T, Soran H. Sphingolipids and deoxysphingolipids in diabetes. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.09.054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
14
|
Croci D, Nevzati E, Hornemann T, Hiroki D, Schöpf S, Coluccia D, Fandino J, Marbacher S, Muroi C. The Role of IL-6, ET-1 in the Pathophysiology of Vasospasm, Delayed Cerebral Injury after Subarachnoid Hemorrhage. J Neurol Surg A Cent Eur Neurosurg 2015. [DOI: 10.1055/s-0035-1564498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Dohrn MF, Othman A, Hirshman SK, Bode H, Alecu I, Fähndrich E, Karges W, Weis J, Schulz JB, Hornemann T, Claeys KG. Elevation of plasma 1-deoxy-sphingolipids in type 2 diabetes mellitus: a susceptibility to neuropathy? Eur J Neurol 2015; 22:806-14, e55. [DOI: 10.1111/ene.12663] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Accepted: 11/28/2014] [Indexed: 12/31/2022]
Affiliation(s)
- M. F. Dohrn
- Department of Neurology; RWTH Aachen University; Aachen Germany
- Institute of Neuropathology; RWTH Aachen University; Aachen Germany
| | - A. Othman
- Institute of Clinical Chemistry; University Hospital Zürich; Zürich Switzerland
- Centre for Integrative Human Physiology; University of Zürich; Zürich Switzerland
| | - S. K. Hirshman
- Department of Neurology; RWTH Aachen University; Aachen Germany
| | - H. Bode
- Institute of Clinical Chemistry; University Hospital Zürich; Zürich Switzerland
- Centre for Integrative Human Physiology; University of Zürich; Zürich Switzerland
| | - I. Alecu
- Institute of Clinical Chemistry; University Hospital Zürich; Zürich Switzerland
- Centre for Integrative Human Physiology; University of Zürich; Zürich Switzerland
| | - E. Fähndrich
- Division of Endocrinology and Diabetes; RWTH Aachen University; Aachen Germany
| | - W. Karges
- Division of Endocrinology and Diabetes; RWTH Aachen University; Aachen Germany
| | - J. Weis
- Institute of Neuropathology; RWTH Aachen University; Aachen Germany
- JARA - Translational Brain Medicine; Aachen Germany
| | - J. B. Schulz
- Department of Neurology; RWTH Aachen University; Aachen Germany
- JARA - Translational Brain Medicine; Aachen Germany
| | - T. Hornemann
- Institute of Clinical Chemistry; University Hospital Zürich; Zürich Switzerland
- Centre for Integrative Human Physiology; University of Zürich; Zürich Switzerland
| | - K. G. Claeys
- Department of Neurology; RWTH Aachen University; Aachen Germany
- Institute of Neuropathology; RWTH Aachen University; Aachen Germany
- JARA - Translational Brain Medicine; Aachen Germany
| |
Collapse
|
16
|
Othman A, Saely C, Drexel H, von Eckardstein A, Hornemann T. Plasma sphingolipid profiling reveals novel distinct biomarkers for predicting cardiovascular disease and type 2 diabetes mellitus. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Sutter I, Riwanto M, Rohrer L, Othman A, Hornemann T, Landmesser U, von Eckardstein A. Low concentrations of sphingosine-1-phosphates and plasmalogens in HDL are associated with coronary artery disease and reduced anti-apoptotic activity of HDL. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.105] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Sutter I, Park R, Othman A, Rohrer L, Hornemann T, Stoffel M, Devuyst O, von Eckardstein A. Apolipoprotein m modulates erythrocyte efflux and urinary excretion of sphingosine-1-phosphate. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Othman A, Säly C, Drexel H, Eckardstein AV, Hornemann T. Prediction of incident diabetes mellitus or coronary artery disease by atypical sphingoid bases. DIABETOL STOFFWECHS 2014. [DOI: 10.1055/s-0034-1375052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Hornemann T, Othman A, Eckardstein AV, Porretta-Serapiglia C, Lauria G, Bianchi R. L-serine supplementation suppresses the formaiton of neurotoxic deoxysphingolipids and improves neuropathy in a type 1 diabetic rat model. DIABETOL STOFFWECHS 2014. [DOI: 10.1055/s-0034-1375013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Kugathasan U, Laurá M, Hornemann T, Skorupinska M, Bull K, Phadke R, Miller K, Lauria G, Lombardi R, Polke J, Koltzenburg M, Houlden H, Reilly M. P53 Identifying responsive outcome measures in hereditary sensory neuropathy type 1 (HSN1). Neuromuscul Disord 2014. [DOI: 10.1016/s0960-8966(14)70069-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Hornemann T. [CME clinical laboratory values 27. Highly sensitive troponins]. Praxis (Bern 1994) 2012; 101:1338-1339. [PMID: 23032503 DOI: 10.1024/1661-8157/a001067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Affiliation(s)
- T Hornemann
- Institut für Klinische Chemie, Universitätsspital Zürich.
| |
Collapse
|
23
|
Aflaki E, Doddapattar P, Radović B, Povoden S, Kolb D, Vujić N, Wegscheider M, Koefeler H, Hornemann T, Graier WF, Malli R, Madeo F, Kratky D. C16 ceramide is crucial for triacylglycerol-induced apoptosis in macrophages. Cell Death Dis 2012; 3:e280. [PMID: 22419109 PMCID: PMC3317349 DOI: 10.1038/cddis.2012.17] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2012] [Revised: 02/02/2012] [Accepted: 02/07/2012] [Indexed: 12/12/2022]
Abstract
Triacylglycerol (TG) accumulation caused by adipose triglyceride lipase (ATGL) deficiency or very low-density lipoprotein (VLDL) loading of wild-type (Wt) macrophages results in mitochondrial-mediated apoptosis. This phenotype is correlated to depletion of Ca(2+) from the endoplasmic reticulum (ER), an event known to induce the unfolded protein response (UPR). Here, we show that ER stress in TG-rich macrophages activates the UPR, resulting in increased abundance of the chaperone GRP78/BiP, the induction of pancreatic ER kinase-like ER kinase, phosphorylation and activation of eukaryotic translation initiation factor 2A, the translocation of activating transcription factor (ATF)4 and ATF6 to the nucleus and the induction of the cell death executor CCAAT/enhancer-binding protein homologous protein. C16:0 ceramide concentrations were increased in Atgl-/- and VLDL-loaded Wt macrophages. Overexpression of ceramide synthases was sufficient to induce mitochondrial apoptosis in Wt macrophages. In accordance, inhibition of ceramide synthases in Atgl-/- macrophages by fumonisin B1 (FB1) resulted in specific inhibition of C16:0 ceramide, whereas intracellular TG concentrations remained high. Although the UPR was still activated in Atgl-/- macrophages, FB1 treatment rescued Atgl-/- macrophages from mitochondrial dysfunction and programmed cell death. We conclude that C16:0 ceramide elicits apoptosis in Atgl-/- macrophages by activation of the mitochondrial apoptosis pathway.
Collapse
Affiliation(s)
- E Aflaki
- Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria
- National Human Genome Research Institute/NIH Molecular Neurogenetics Section, 35 Convent Drive, Bethesda, MD, USA
| | - P Doddapattar
- Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria
| | - B Radović
- Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria
| | - S Povoden
- Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria
| | - D Kolb
- Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria
- Center for Medical Research, Medical University of Graz, Stiftingtalstrasse 24, 8010 Graz, Austria
| | - N Vujić
- Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria
| | - M Wegscheider
- Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria
| | - H Koefeler
- Institute of Cell Biology, Histology and Embryology, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria
| | - T Hornemann
- Institute of Clinical Chemistry, University of Zurich, Rämistrasse 100, 8091 Zürich, Switzerland
| | - W F Graier
- Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria
| | - R Malli
- Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria
| | - F Madeo
- Institute of Molecular Biosciences, University of Graz, Humboldtstrasse 50, 8010 Graz, Austria
| | - D Kratky
- Institute of Molecular Biology and Biochemistry, Center of Molecular Medicine, Medical University of Graz, Harrachgasse 21, 8010 Graz, Austria
| |
Collapse
|
24
|
Murphy S, Laurá M, Ernst D, Liu YT, Blake J, Donaghy M, Winer J, Houlden H, Hornemann T, Reilly M. P46 Clinical and genetic characterisation of hereditary sensory neuropathy type 1 caused by mutations in SPTLC2. Neuromuscul Disord 2012. [DOI: 10.1016/s0960-8966(12)70054-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
25
|
Matilde L, Eichler F, Hornemann T, Murphy SM, Polke J, Bull K, Houlden H, Reilly MM. 1042 Hereditary sensory and autonomic neuropathy type 1: correlation of severity and plasma atypical deoxy-sphyngoid bases. J Neurol Neurosurg Psychiatry 2012. [DOI: 10.1136/jnnp-2011-301993.16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
26
|
Lauraá M, Murphy S, Hornemann T, Bode H, Polke J, Blake J, Houlden H, Reilly M. P42 Hereditary sensory neuropathy type 1: correlation of severity and plasma atypical deoxy-sphyngoid bases. Neuromuscul Disord 2012. [DOI: 10.1016/s0960-8966(12)70050-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
27
|
Othman A, Rütti MF, Ernst D, Saely CH, Rein P, Drexel H, Porretta-Serapiglia C, Lauria G, Bianchi R, von Eckardstein A, Hornemann T. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia 2012; 55:421-31. [PMID: 22124606 DOI: 10.1007/s00125-011-2384-1] [Citation(s) in RCA: 102] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2011] [Accepted: 10/10/2011] [Indexed: 01/04/2023]
Abstract
AIMS/HYPOTHESIS Sphingolipid synthesis is typically initiated by the conjugation of L-serine and palmitoyl-CoA, a reaction catalysed by serine palmitoyltransferase (SPT). SPT can also metabolise other acyl-CoAs (C(12) to C(18)) and other amino acids such as L-alanine and glycine, giving rise to a spectrum of atypical sphingolipids. Here, we aimed to identify changes in plasma levels of these atypical sphingolipids to explore their potential as biomarkers in the metabolic syndrome and diabetes. METHODS We compared the plasma profiles of ten sphingoid bases in healthy individuals with those of patients with the metabolic syndrome but not diabetes, and diabetic patients (n = 25 per group). The results were verified in a streptozotocin (STZ) rat model. Univariate and multivariate statistical analyses were used. RESULTS Deoxysphingolipids (dSLs) were significantly elevated (p = 5 × 10⁻⁶) in patients with the metabolic syndrome (0.11 ± 0.04 μmol/l) compared with controls (0.06 ± 0.02 μmol/l) but did not differ between the metabolic syndrome and diabetes groups. Levels of C(16)-sphingosine-based sphingolipids were significantly lowered in diabetic patients but not in patients with the metabolic syndrome but without diabetes (p = 0.008). Significantly elevated dSL levels were also found in the plasma and liver of STZ rats. A principal component analysis revealed a similar or even closer association of dSLs with diabetes and the metabolic syndrome in comparison with the established biomarkers. CONCLUSIONS/INTERPRETATION We showed that dSLs are significantly elevated in patients with type 2 diabetes mellitus and non-diabetic metabolic syndrome compared with healthy controls. They may, therefore, be useful novel biomarkers to improve risk prediction and therapy monitoring in these patients.
Collapse
Affiliation(s)
- A Othman
- Institute for Clinical Chemistry, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Penno A, Eichler F, Hornemann T. Accumulation of two atypical sphingolipids underlies the pathology in hereditary sensory neuropathy HSAN1. Chem Phys Lipids 2009. [DOI: 10.1016/j.chemphyslip.2009.06.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Hornemann T, Penno A, von Eckardstein A. The accumulation of two atypical sphingolipids cause hereditary sensory neuropathy type 1 (HSAN1). Chem Phys Lipids 2008. [DOI: 10.1016/j.chemphyslip.2008.05.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Penno A, von Eckardstein A, Hornemann T. SPTLC3 subunit of serine palmitoyltransferase is responsible for the generation of short chain sphingoid bases. Chem Phys Lipids 2008. [DOI: 10.1016/j.chemphyslip.2008.05.110] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Kraft T, Hornemann T, Stolz M, Nier V, Wallimann T. Coupling of creatine kinase to glycolytic enzymes at the sarcomeric I-band of skeletal muscle: a biochemical study in situ. J Muscle Res Cell Motil 2001; 21:691-703. [PMID: 11227796 DOI: 10.1023/a:1005623002979] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The specific interaction of muscle type creatine-kinase (MM-CK) with the myofibrillar M-line was demonstrated by exchanging endogenous MM-CK with an excess of fluorescently labeled MM-CK in situ, using chemically skinned skeletal muscle fibers and confocal microscopy. No binding of labeled MM-CK was noticed at the I-band of skinned fibers, where the enzyme is additionally located in vivo, as shown earlier by immunofluorescence staining of cryosections of intact muscle. However, when rhodamine-labeled MM-CK was diffused into skinned fibers that had been preincubated with phosphofructokinase (PFK), a glycolytic enzyme known to bind to actin, a striking in vivo-like interaction of Rh-MM-CK with the I-band was found, presumably mediated by binding of Rh-MM-CK to the glycolytic enzyme. Aldolase, another actin-binding glycolytic enzyme was also able to bind Rh-MM-CK to the I-band, but formation of the complex occurred preferably at long sarcomere length (> 3.0 microm). Neither pyruvate kinase, although known for its binding to actin, nor phosphoglycerate kinase (PGK), not directly interacting with the I-band itself, did mediate I-band targeting of MM-CK. Anchoring of MM-CK to the I-band via PFK, but not so via aldolase, was strongly pH-dependent and occurred below pH 7.0. Labeling performed at different sarcomere length indicated that the PFK/MM-CK complex bound to thin filaments of the I-band, but not within the actomyosin overlap zones. The physiological consequences of the structural interaction of MM-CK with PFK at the I-band is discussed with respect to functional coupling of MM-CK to glycolysis, metabolic regulation and channeling in multi-enzyme complexes. The in situ binding assay with skinned skeletal muscle fibers described here represents a useful method for further studies of specific protein-protein interactions in a structurally intact contractile system under various precisely controlled conditions.
Collapse
Affiliation(s)
- T Kraft
- Swiss Federal Institute of Technology, Institute of Cell Biology, ETH Zürich.
| | | | | | | | | |
Collapse
|
32
|
Abstract
The dimeric chicken brain type isoenzyme of creatine kinase (BB-CK) was mutated by a C283S amino acid exchange in the catalytic site to produce a basically inactive dimer (B*B*-CK). The mutated enzyme showed a residual activity of about 4% compared to the wild-type, whereas substrate binding parameters were not altered. The inactivated dimer was hybridized with native dimeric muscle enzyme (MM-CK) to produce a partially inactivated MB*-CK heterodimeric hybrid and also to a his-tagged BB-CK (hBhB-CK) resulting in a partially inactive hBB*-CK homodimer. The generated hybrids were purified by chromatography. The V(max) and substrate binding parameters K(m) and K(d) were determined for both directions of the CK reaction and compared to the parameters of the wild-type enzymes (MM-, BB-, hBhB-, MB-CK). In the direction of ATP synthesis (reverse reaction), the MB*- and hBB*-CK hybrids showed a decrease of V(max) to 34% and 32%, respectively, compared to the unmodified wild-type isoform. The inactivation of a single subunit in MB*-CK led to an increase in the K(d) value resulting in an significant substrate synergism, not seen with the MB-CK wild-type enzyme. In the direction of phosphocreatine synthesis (forward reaction), the modified hybrids showed a decrease of V(max) to 50% of the wild-type enzymes and no significant alterations of the K(m) and K(d) parameters. These results strongly suggest an enzymatic cooperativity of the two subunits in the reverse reaction but independent catalytic function in the forward reaction.
Collapse
Affiliation(s)
- T Hornemann
- Swiss Federal Institute of Technology, Institute of Cell Biology HPM F44, ETHZ-Hönggerberg, 8093, Zürich, Switzerland.
| | | | | |
Collapse
|
33
|
Hornemann T, Stolz M, Wallimann T. Isoenzyme-specific interaction of muscle-type creatine kinase with the sarcomeric M-line is mediated by NH(2)-terminal lysine charge-clamps. J Cell Biol 2000; 149:1225-34. [PMID: 10851020 PMCID: PMC2175123 DOI: 10.1083/jcb.149.6.1225] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Creatine kinase (CK) is located in an isoenzyme-specific manner at subcellular sites of energy production and consumption. In muscle cells, the muscle-type CK isoform (MM-CK) specifically interacts with the sarcomeric M-line, while the highly homologous brain-type CK isoform (BB-CK) does not share this property. Sequence comparison revealed two pairs of lysine residues that are highly conserved in M-CK but are not present in B-CK. The role of these lysines in mediating M-line interaction was tested with a set of M-CK and B-CK point mutants and chimeras. We found that all four lysine residues are involved in the isoenzyme-specific M-line interaction, acting pair-wise as strong (K104/K115) and weak interaction sites (K8/K24). An exchange of these lysines in MM-CK led to a loss of M-line binding, whereas the introduction of the very same lysines into BB-CK led to a gain of function by transforming BB-CK into a fully competent M-line-binding protein. The role of the four lysines in MM-CK is discussed within the context of the recently solved x-ray structures of MM-CK and BB-CK.
Collapse
Affiliation(s)
- T Hornemann
- Swiss Federal Institute of Technology, Institute of Cell Biology, Eidenössisch Technische Hochschule Zürich Hönggerberg, 8093 Zürich, Switzerland.
| | | | | |
Collapse
|
34
|
Wallimann T, Dolder M, Schlattner U, Eder M, Hornemann T, Kraft T, Stolz M. Creatine kinase: an enzyme with a central role in cellular energy metabolism. MAGMA 1998; 6:116-9. [PMID: 9803379 DOI: 10.1007/bf02660927] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- T Wallimann
- Institute of Cell Biology, ETH-Hönggerberg, Zürich, Switzerland
| | | | | | | | | | | | | |
Collapse
|
35
|
Wallimann T, Dolder M, Schlattner U, Eder M, Hornemann T, O'Gorman E, Rück A, Brdiczka D. Some new aspects of creatine kinase (CK): compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology. Biofactors 1998; 8:229-34. [PMID: 9914824 DOI: 10.1002/biof.5520080310] [Citation(s) in RCA: 169] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Creatine kinase (CK) isoenzymes, specifically located at places of energy demand and energy production, are linked by a phosphocreatine/creatine (PCr/Cr) circuit, found in cells with intermittently high energy demands. Cytosolic CKs, in close conjunction with Ca(2+)-pumps, play a crucial role for the energetics of Ca(2+)-homeostasis. Mitochondrial Mi-CK, a cuboidal-shaped octamer with a central channel, binds and crosslinks mitochondrial membranes and forms a functionally coupled microcompartment with porin and adenine nucleotide translocase for vectorial export of PCr into the cytosol. The CK system is regulated by AMP-activated protein kinase via PCr/Cr and ATP/AMP ratios. Mi-CK stabilizes and cross-links cristae- or inner/outer membranes to form parallel membrane stacks and, if overexpressed due to creatine depletion or cellular energy stress, forms those crystalline intramitochondrial inclusions seen in some mitochondrial cytopathy patients. Mi-CK is a prime target for free radical damage by peroxynitrite. Mi-CK octamers, together with CK substrates have a marked stabilizing and protective effect against mitochondrial permeability transition pore opening, thus providing a rationale for creatine supplementation of patients with neuromuscular and neurodegenerative diseases.
Collapse
Affiliation(s)
- T Wallimann
- Institute of Cell Biology, ETH-Hönggerberg, Zürich, Switzerland.
| | | | | | | | | | | | | | | |
Collapse
|